Chronic diseases present a significant challenge to 21st century global health policy. In developing nations, the growing prevalence of chronic diseases such as chronic kidney disease has severe implications on health and economic output. The rapid rise of common risk factors such as diabetes, hypertension, and obesity, especially among the poor, will result in even greater and more profound burdens that developing nations are not equipped to handle. Attention to chronic diseases, chronic kidney disease in particular, has been lacking, largely due to the global health community’s focus on infectious diseases and lack of awareness. There is a critical need for funding in and to developing countries to implement more comprehensive, cost-effective, and preventative interventions against chronic diseases. This paper examines the epidemiology of chronic diseases, the growing prevalence of chronic kidney disease and its implications for global public health, and the associated health and economic burdens. Finally, a summary review of cost-effective interventions and funding needs is provided.

Keywords:
Chronic diseases, Chronic kidney disease, Developing countries, Economic impact, Cost-effective intervention
1.
World Health Organization: The Global Burden of Disease: 2004 Update. Geneva, WHO, 2008.
2.
World Health Organization: Preventing Chronic Diseases: A Vital Investment. Geneva, WHO, 2005.
3.
World Bank: Addressing the Challenge of Non-Communicable Diseases in Brazil, 2005.
4.
Murray C, Lopez A: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Harvard University Press, 1996.
5.
World Health Organization: The World Health Report 2002 – Reducing Risks, Promoting Healthy Life. Geneva, WHO, 2002.
6.
Codreanu I, et al: Prevention programmes of progressive renal disease in developing nations. Nephrology (Carlton) 2006;11:321–328.
7.
Levey AS, et al: Chronic kidney disease as a global public health problem: approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247–259.
8.
Jungers P, et al: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997;12:2597–2602.
9.
Foley RN, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186–192.
10.
Atkins RC: The epidemiology of chronic kidney disease. Kidney Int Suppl 2005;94:S14–S18.
11.
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):S1–S266.
12.
Sumaili EK, et al: High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. BMC Nephrol 2009;10:18.
13.
Hossain MP, et al: CKD and poverty: a growing global challenge. Am J Kidney Dis 2009;53:166–174.
14.
Zhang L, et al: Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis 2008;51:373–384.
15.
Vachvanichsanong P, Dissaneewate P, McNeil E: Childhood chronic kidney disease in a developing country. Pediatr Nephrol 2008;23:1143–1147.
16.
Perico N, et al: Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrol Dial Transplant 2009;24:1355–1358.
17.
Levey AS, et al: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089–2100.
18.
Chadban SJ, et al: Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2003;14(suppl 2):S131–S138.
19.
Chen W, et al: Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant 2009;24:1205–1212.
20.
Zhang L, et al: Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007;22:1093–1099.
21.
Yach D, et al: The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004;291:2616–2622.
22.
Beaglehole R, Yach D: Globalisation and the prevention and control of non-communicable disease: the neglected chronic diseases of adults. Lancet 2003;362:903–908.
23.
Ezzati M, et al: Rethinking the ‘diseases of affluence’ paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med 2005;2:e133.
24.
Monteiro CA, et al: Obesity and inequities in health in the developing world. Int J Obes Relat Metab Disord 2004;28:1181–1186.
25.
World Bank: Public Policy and the Challenge of Chronic Non-Communicable Disease. Washington, 2007.
26.
Agarwal SK, Srivastava RK: Chronic kidney disease in India: challenges and solutions. Nephron Clin Pract 2009;111:c197–c203, discussion c203.
27.
Bumgarner R: Non-communicable disease issues and options revisited. Soc Prev Med 2004;38:202–210.
28.
Leeder S, Raymond S, Greenberg H: A Race against Time: The Challenge of Cardiovascular Disease in Developing Economies. New York, Columbia University, 2004.
29.
International Diabetes Federation: Diabetes Atlas, ed 2. Brussels, International Diabetes Federation, 2003.
30.
Srinath Reddy K, et al: Responding to the threat of chronic diseases in India. Lancet 2005;366:1744–1749.
31.
World Bank: PovertyNet, Washington, 2010.
32.
Ito J, et al: Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam. Nephron Clin Pract 2008;109:c25–c32.
33.
Parving HH, Lewis JB, Ravid M: Prevalence and Risk Factors for Microalbuminuria in Type 2 Diabetic Patients: A Global Perspective. Copenhagen, Steno Diabetes Center, 2004.
34.
Remuzzi G, Weening J: Albuminuria as early test for vascular disease. Lancet 2005;365:556–557.
35.
Lysaght MJ: Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13(suppl 1):S37–S40.
36.
Arogundade FA, Barsoum RS: CKD prevention in Sub-Saharan Africa: a call for governmental, nongovernmental, and community support. Am J Kidney Dis 2008;51:515–523.
37.
Jafar TH: The growing burden of chronic kidney disease in Pakistan. N Engl J Med 2006;354:995–997.
38.
Abegunde D, Stanciole A: An Estimation of the Economic Impact of Chronic Noncommunicable Diseases in Selected Countries. Geneva, WHO, 2006.
39.
Henry-Lee A, Yearwood A: Protecting the Poor and the Medically Indigent under Health Insurance: A Case Study of Jamaica. Bethesda, Partnerships for Health Reform Project, 1999.
40.
Heeley E, et al: Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke 2009;40:2149–2156.
41.
International Diabetes Federation: Diabetes Atlas, ed 3. Brussels, International Diabetes Center, 2007.
42.
Barsoum RS: Chronic kidney disease in the developing world. N Engl J Med 2006;354:997–999.
43.
Puska P: Successful prevention of non-communicable diseases: 25 year experiences with North Karelia Project in Finland. Public Health Med 2002;4:5–7.
44.
Gaziano T, Galea G, Reddy K: Scaling up interventions for chronic disease prevention: the evidence. Lancet 2007;370:1939–1946.
45.
Iseki K: Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem. J Nephrol 2008;21:305–312.
46.
Williams B, et al: British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634–640.
47.
Tseng K: Standards of medical care in diabetes – 2006. Diabetes Care 2006;29(suppl 1):S4–S42.
48.
Hallan S, et al: Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006;333:1047.
49.
Ruggenenti P, et al: Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney Int 2001;59:286–294.
50.
Palmer AJ, et al: An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. J Hum Hypertens 2004;18:733–738.
51.
Yach DY, Hawkes C: Towards a WHO Long-Term Strategy for Prevention and Control of Leading Non-Communicable Diseases. Geneva, WHO, 2004.
52.
Jamison D, Mosley W, Measham A: Disease Control Priorities in Developing Countries. Washington, World Bank, 2006.
53.
Coresh J, et al: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12.
54.
Kher V: End-stage renal disease in developing countries. Kidney Int 2002;62:350–362.
55.
Mathers CD: Towards valid and comparable measurement of population health. Bull World Health Organ 2003;81:787–788.
56.
Nugent R, Feigl A: Where Have All the Donors Gone? Scarce Donor Funding for Non-Communicable Diseases. CGD Working Paper 228. Washington, Center for Global Development, 2010.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.